Research Article

Methicillin- and Inducible Clindamycin-Resistant Staphylococcus aureus among Patients with Wound Infection Attending Arba Minch Hospital, South Ethiopia

Mohammedaman Mama^{(b), 1} Addis Aklilu,² Kassahun Misgna,³ Molla Tadesse,⁴ and Eyerusalem Alemayehu⁵

¹Department of Medical Laboratory Sciences, Madda Walabu University Goba Referral Hospital, Bale-Goba, Ethiopia
²Department of Medical Laboratory Sciences, Arba Minch University, Arba Minch, Ethiopia
³Black Lion Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia
⁴Kebridehar Primary Hospital, Ethio-Somale, Ethiopia
⁵Arba Minch Hospital, Arba Minch, Ethiopia

Correspondence should be addressed to Mohammedaman Mama; muheekoo@gmail.com

Received 5 December 2018; Accepted 11 March 2019; Published 1 April 2019

Academic Editor: Barbara H. Iglewski

Copyright © 2019 Mohammedaman Mama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Wound infection is one of the most common hospital-acquired infections. Different bacteria cause infection, of which *Staphylococcus aureus* is one of the known bacteria in causing infection with increased drug-resistant isolates. *Objective*. To assess the prevalence and antimicrobial susceptibility pattern of methicillin and inducible clindamycin-resistant *Staphylococcus aureus* among patients with wound infections attending Arba Minch Hospital. *Methods*. A facility-based cross-sectional study was conducted from April to June 2017. A pretested questionnaire was used to collect demographic data and clinical characteristics. Wound swabs were cultured and identified by standard techniques. Antibiotic susceptibility tests were performed by the Kirby–Bauer disc diffusion method. Methicillin resistance was detected using the cefoxitin (30 μ g) antibiotic disc while inducible clindamycin resistance was detected by the D-zone test. The data were analyzed using Statistical Package for Social Science, version 20. *p* value <0.05 was considered statistically significant. *Results*. A total of 161 patients were enrolled and a majority of them were female (90, 50.9%). Among the collected samples, 79 (49.7%) were positive for *S. aureus*; of this, methicillin resistance accounted for 65 (82.3%). Out of 22 (27.8%) erythromycin-resistant isolates, 19 (24.1%) showed inducible clindamycin resistance. Methicillin-resistant *S. aureus* showed higher resistance against tetracycline (72.3%) followed by cotrimoxazole (43.1%) and 100% sensitivity to vancomycin. The overall prevalence of inducible clindamycin resistance against other therapeutic options like clindamycin is becoming an obstacle in the treatment of infections which need attention from concerned bodies.

1. Introduction

Wound infection is one of the known hospital-acquired infections responsible for significant human mortality and morbidity worldwide [1]. Wound infection results in sepsis, disfiguring, amputation, limb loss, long hospital stays, and higher costs [2, 3]. Infections of wounds can be caused by different microorganisms, like *Staphylococcus aureus* (*S. aureus*), *Pseudomonas aeruginosa* (*P. aeruginosa*), *Escherichia coli* (*E. coli*), and *Enterococcus* [4, 5]. *Staphylococcus*

aureus is a Gram-positive bacterium which is a major causative agent of different skin infections such as surgical site infections, burns, and wounds [6, 7].

Methicillin-resistant *S. aureus* (MRSA) is a highly infectious strain of the ordinary *S. aureus* bacteria that is able to withstand the curative ability of commonly used antibiotics. Methicillin resistance of *S. aureus* is due to the acquisition of mecA gene that encodes for penicillin-binding protein 2a, which has low affinity to methicillin. Methicillinresistant *S. aureus* is a serious concern not only because of 2

resistant to methicillin but also because of developing resistant to other commonly used antibiotics in the hospitals that limited therapeutic options to few expensive drugs like vancomycin [7–9].

The increasing incidence of methicillin resistance among *Staphylococci* has led to renewed interest in the usage of macrolide-lincosamide-streptogramin B (MLSB) antibiotics to treat *S. aureus* infections, with clindamycin being the preferable agent due to its excellent pharmacokinetic properties [10, 11]. However, widespread use of MLSB antibiotics has led to an increase in the number of *Staphylococcal* strains acquiring resistance to MLSB antibiotics [12–14].

Methicillin-resistant S. aureus is found worldwide with an estimated colonization rate ranging from 11 to 40% in specific populations with more than 50% of these estimated to develop the infection [8, 15, 16]. Methicillin-resistant S. aureus infection kills more Americans each year than HIV/ AIDS, Parkinson's disease, emphysema, and homicide combined in USA [15]. Despite the advances in modern medicine, wound infection still poses a risk of increased morbidity and mortality to patients. Even though many studies have analyzed the prevalence and antimicrobial susceptibility pattern of MRSA, there is still an increasing prevalence of MRSA [17]. Therefore, this study was aimed to assess the prevalence and antimicrobial susceptibility pattern of methicillin and induced clindamycin-resistant S. aureus among patients with wound infection attending Arba Minch Hospital.

2. Materials and Methods

2.1. Study Design, Area, and Period. A hospital-based crosssectional study was conducted at Arba Minch Hospital, from April to June 2017. Arba Minch Hospital in Arba Minch town, Gamo Gofa Zone, is situated 505 km south of Addis Ababa at an elevation of 1285 meters above sea level. The hospital gives service for more than 100 thousand people in Arba Minch and surrounding woredas.

2.2. Sample Size Determination and Sampling Technique. The sample size was obtained using sample size determination formula for the estimation of the single population proportion. p value of 0.12 for MRSA was taken from the previous study [10] with 95% confidence interval (z = 1.96) and 5% marginal error (d = 0.05). The final sample size was 180 which includes 10% nonresponse rate. Systematic sampling technique was used to select patients with wound infection during the study period using K^{th} interval. The first patient was selected by the lottery method from the first three patients, and the rest of the study participants were selected in every 3 patients.

2.3. Data Collection, Sample Collection, and Transportation. A pretested structured questionnaire was used to collect sociodemographic data and clinical factors. Open wound swabs were aseptically obtained after the wound immediate surface exudates and contaminants were cleaned off with

moistened sterile gauze and sterile normal saline solution. Dressed wounds were cleansed with sterile normal saline after removing the dressing. The specimen was collected on sterile cotton swab by rotating with sufficient pressure. The samples were transported to Medical Microbiology and Parasitology Laboratory of Arba Minch University within thirty minutes after collection using Amies transport media.

2.4. Inoculation and Identification. The collected samples were immediately processed for bacteriological analysis. Swabs collected were streaked on Mannitol salt agar by using a swab containing the sample on one-sixth of the media and then spread throughout the media by sterile inoculation loop. The plates were incubated at 37° C for 24–48 hours. Preliminary identification of bacteria was based on colony characteristics of the organisms like growth on Mannitol salt agar, gram reaction, and catalase and slide coagulase and test tube coagulase for slide coagulase-negative test results.

2.5. Detection of MRSA. Methicillin-resistant S. aureus was identified phenotypically based on its resistance to oxacillin $(1 \ \mu g)$ and cefoxitin $(30 \ \mu g)$ (Oxoid, Basingstoke, UK) by the disc diffusion method performed on modified Muller-Hinton agar (Oxoid, Basingstoke, UK). Based on the CLSI, 2016 guideline, the zone of inhibition is interpreted and grouped into methicillin-sensitive and methicillin-resistant S. aureus [18].

2.6. Detection of Inducible Clindamycin Resistance. A lawn culture of the isolates adjusted to 0.5 McFarland's turbidity was made on a Mueller-Hinton agar plate, and discs of clindamycin $(2 \mu g)$ and erythromycin $(15 \mu g)$ (Oxoid, Basingstoke, UK) were placed at a distance of 15 mm apart as per the Clinical Laboratory Standard Institute (CLSI, 2016) recommendations, along with routine antibiotic susceptibility testing. This interpretation was done only for erythromycin-resistant *S. aureus* strains. Induction test results were read at 16 to 18 h.

D phenotype (inducible MLSB) erythromycin (ERY) resistant (R), clindamycin (CLI) sensitive (S) (blunted, D-shaped clear zone around CLI disk proximal to the ERY disk); D⁺ phenotype (inducible MLSB) ERY R, CLI S (blunted, D-shaped zone around CLI disk proximal to the ERY disk and small colonies growing to CLI disk in otherwise clear zone); Neg phenotype (MSB) ERY R, CLI S (clear zone around CLI disk); HD phenotype (constitutive MLSB) ERY R, CLI R (two zones of growth appear around CLI disk: one zone is light, hazy growth extending from the CLI disk to the second zone where the growth is much heavier; the inner, hazy zone is blunted proximal to the ERY disk as in phenotype D; R phenotype (constitutive MSB): no hazy zone, growth up to CLI and ERY disks; S phenotype (no resistance) ERY R, CLI S (clear, susceptible zone diameters). All isolates showing positive induction test results (i.e., a blunted or "D-shaped" zone) and a subset of isolates with other induction test results were read again at 24 h [18].

2.7. Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing was performed by Kirby-Bauer disk diffusion technique according to the criteria set by CLSI (2016). Two to five pure colonies were transferred into a tube containing 5 ml nutrient broth and mixed gently until it forms a homogenous suspension. Then, turbidity of the suspension was adjusted to the optical density of McFarland 0.5 tubes in order to standardize the inoculum size. A sterile cotton swab was then dipped into the suspension. The swab was then used to distribute the bacteria suspension evenly over the entire surface of Mueller-Hinton agar. Antibiotics (Oxoid, Basingstoke, UK) which are found around the study area and recommended by CLSI for susceptibility test were erythromycin $(15 \,\mu g)$, ciprofloxacin $(30 \,\mu g)$, chlorampheni $col (30 \mu g)$, trimethoprim-sulfamethoxazole (cotrimoxazole) $(1.25/23.75 \,\mu\text{g})$, amikacin $(10 \,\mu\text{g})$, clindamycin $(2 \,\mu\text{g})$, tetracycline (30 μ g), gentamicin (10 μ g), and vancomycin (Etest for MIC) (Oxoid, Basingstoke, UK). Then, the inoculated plates were left at room temperature to dry for 3-5 minutes. Using a sterile forceps, the antibiotic discs were placed on the inoculated plates and then incubated at 37°C for 18-24 hours. The diameter of the zone of inhibition around the disc was measured to the nearest millimeter using a ruler, and the isolates were classified as sensitive and resistant using CLSI standard [18].

2.8. Data Quality Control. Data quality was ensured from data collection up to final laboratory identification by following the prepared standard operating procedure (SOP). Five percent of the questionnaire was pretested prior to data collection in Arba Minch Health Center and modified accordingly. Data collection process was monitored on daily basis, and incompletely filled questionnaires were discarded. The performance of the prepared media was checked by inoculating control strain S. aureus ATCC 29213, which was obtained from Ethiopian Public Health Institute (EPHI). Culture media were prepared according to the manufacturer's instruction, and the sterility was checked by incubating 5% of prepared media at 37°C overnight and observing bacterial growth. Those batches of the media that show the growth was discarded and reprepared. The performance of antibiotic discs was checked by using Enterococcus faccalis ATCC 29122 and cotrimoxazole disc, and it should measure the inhibition zone greater than 19 mm.

2.9. Data Analysis. Data were collected, entered, cleaned, and analyzed using SPSS version 20 software according to the study objectives. The descriptive summaries were presented with text, tables, and figures. Binary logistic regression analysis was made to obtain odds ratio and confidence interval of statistical associated variables. All variables with p < 0.25 in the bivariate analysis were included in the final multivariate analysis. p value less than 0.05 was considered as statistically significant. Finally, the magnitude of association between different variables in relation to the outcome variable was measured by odds ratio with 95% confidence interval.

3. Results

3.1. Overall Sociodemographic and Clinical Characteristics of Study Participants. A total of 161 patients were enrolled in this study with a nonresponse rate of 11.6%. The majority of the study participants were female (90, 55.9%). According to age category, patients in the age range of 15–30 years account the most (80, 49.7%). The mean age of the study participants were urban dwellers (96, 59.6%), whereas 105 (65.2%) were literate. Study participants who developed wound infection after surgery were 53 (32.9%), and more than 90% of the study participants had the history of previous antibiotic usage for the last one year (Table 1).

3.2. Prevalence of MRSA among Sociodemographic and Clinical Characteristics. From 161 cultivated samples, a total of 79 (49.7%) isolated *S. aureus* isolates were isolated and screened for methicillin resistance as described in Section 2. Of this, methicillin-resistant *S. aureus* accounts 65 (82.27%) isolates, while the remaining isolates were methicillin-sensitive *Staphylococcus aureus* (MSSA). Majority of the MRSA isolates were recovered from male participants (35, 53.84%), urban dwellers (45, 69.23%), in the age range of 16–30 years (30, 46.15%). The participants who had a skin lesion and surgery showed a greater acquisition of MRSA (19, 29.23%) and (20, 30.54%), respectively (Tables 2 and 3).

3.3. Prevalence of MRSA and Associated Factors. As shown in Tables 2 and 3, different sociodemographic factors were assessed for possible association with MRSA infection among the study participants. The results of the study showed that 53.8% of male and 46.6% female participants were found to be infected with MRSA. The prevalence of infection with MRSA has an initial association with the sex of the respondents (*p* = 0.041, COR: 0.514, 95% CI (0.271–0.975)). However, the association was not significant after adjusting for confounders using multivariate logistic regression (p = 0.117). Study participants residing in urban area were found to have a high percentage (69.2%) of infection as compared to rural area. The association between residence and MRSA infection was statistically significant (p = 0.042, COR: 0.504, 95% CI (0.260-0.976)). However, after adjusting for possible confounders by multivariate logistic regression, the prevalence of infection was not found to be statistically significantly different among urban and rural residents (p = 0.172). Generally, there was no statistically significant association between the prevalence of MRSA and associated factors.

3.4. Antimicrobial Susceptibility Pattern. Identified isolates of *S. aureus* were tested against nine antibiotics as presented in Table 4. Both methicillin-resistant and susceptible *S. aureus* showed 100% susceptibility to amikacin and vancomycin. Furthermore, methicillin-sensitive *S. aureus* showed an additional 100% susceptibility to clindamycin and gentamycin. On the other hand, all isolates showed greater resistance against tetracycline (56, 70.9%), cotrimoxazole (31, 39.2%),

TABLE 1: Sociodemographic and clinical characteristics of patients with wound infection attending Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

Variables	Characteristics	Frequency, n (%)		
Sex	Male	71 (44.1)		
JEA	Female	90 (55.9)		
	≤15	24 (14.9)		
	15-30	80 (49.7)		
Age	30-45	32 (19.9)		
	45-60	22 (13.7)		
	≥60	3 (1.9)		
Residence	Urban	96 (59.6)		
Residence	Rural	65 (40.4)		
	Illiterate	56 (34.8)		
Education	Literate	105 (65.2)		
	Student	42 (26.1)		
	Housewife	42 (26.1)		
	Labor	9 (5.6)		
Occupation	Employee	31 (19.3)		
*	Private	21 (13)		
	Farmer	8 (5)		
	Jobless	8 (5)		
	Hypertension	17 (10.6)		
	ТВ	8 (5)		
Clinical diseases	Diabetes	20 (12.4)		
	HIV	16 (9.9)		
	No chronic disease	100 (62.1)		
	Trauma	17 (10.6)		
	Burn	22 (13.7)		
Type of wound	Surgical site	53 (32.9)		
	Skin abrasion	48 (29.9)		
	Others	21 (13)		
Previous wound infection	Yes	97 (60.2)		
Previous wound infection	No	64 (39.8)		
Durania an til i di	Yes	148 (91.8)		
Previous antibiotic usage	No	13 (8.1)		
	1 day	36 (22.4)		
TT : 1 (2-4 days	61 (37.9)		
Hospital stay	5–6 days	19 (11.8)		
	>week	45 (28)		

and erythromycin (22, 27.8%). Specifically, MRSA strains showed the high resistance of tetracycline (72.3%), cotrimoxazole (43.1%), erythromycin (29.2%), and chloramphenicol (27.7%) and least resistance to clindamycin (3.1%).

3.5. Prevalence of Inducible Clindamycin Resistance. From 79 S. aureus isolates tested for determination of inducible clindamycin resistance, 65 (82.3%) were MRSA and 14 (17.3%) isolates were MSSA (Table 3). Sensitivity to both erythromycin and clindamycin was significantly higher in MRSA compared to MSSA isolates. Resistance to methicillin, erythromycin, and clindamycin was observed in 65 (82.3%), 22 (27.8%), and 2 (2.53%) of the isolates, respectively. Inducible clindamycin resistance was determined in 19 (24.1%) isolates (D-test positive, Figure 1).

As shown in Table 5, inducible MSL_B phenotype predominated (24.6% MRSA; 21.4% MSSA) followed by cMLS_B (3.1% MRSA; 0% MSSA) and MS phenotypes (1 MRSA; 0 MSSA).

3.6. Prevalence of Multidrug-Resistant Isolates. In this study, multidrug-resistant (MDR) status of *S. aureus* was tested against 9 classes of antibiotics. Accordingly, the overall rate of MDR (three and greater than three classes of antibiotics) of *S. aureus* isolates was 27.8% and 29.2% for MRSA. In addition to this, 20% of MRSA isolates showed resistance to one antibiotic class and 16.9% were sensitive to all checked antibiotic classes (Figure 2).

4. Discussion

Methicillin-resistant *S. aureus* has long been recognized as an important pathogen in human disease and is the most common cause of nosocomial infections [19]. The development of resistance against the therapeutic options for treatment of infection caused by MRSA is an emerging problem [1, 2, 7]. Therefore, this study was aimed to assess the prevalence and antimicrobial susceptibility pattern of methicillin-resistant and inducible clindamycin-resistant *S. aureus* among patients with wound infection.

This study showed that the recovery rate of MRSA was greater in male (35, 53.84%) patients with surgery (20, 30.54%) followed by patients with an infection after skin abrasion (19, 29.23%). Other studies performed in Jordan [20] and Uganda [21] reported the same result as in the present study. This may be attributed to the fact that men are mainly involved in occupations that most likely lead to trauma formation compared to women.

Out of 65 MRSA isolates, 30 (46.23%) were recovered from patients in the age range of 15–30 years. This is in line with a study conducted in Bangalore, India [14]. Patients who were hospitalized for more than 1 week harbored more MRSA isolates and those who took antibiotics previously within the last one year were found to be high and isolation of MRSA was also high. This is in agreement with the research performed in Cameroon [22] and India [14]. However, there was no statistically significant association between the prevalence of MRSA and associated factors in this study. This may be due to the smaller sample size included in our study.

Regarding associated factors assessed in the present study, wound infection was not associated with associated factors like use of antibiotics and previous wound infection known to predispose to infection. This finding is in agreement with the previous study performed in Greece [23] and Ethiopia [24]. Similarly, sociodemographic factors (age, sex, and educational status) did not show statistically significant association with wound infection which is in line with the study performed in Hawassa [25] and DebreMarkos [24].

In the present study, the overall prevalence of *S. aureus* was 79 (49.7%) which was in agreement with the study done in Hatay, Turkey [9], Kumasi, Ghana [26], and Yekatit 12 Hospital, Addis Ababa, Ethiopia [27]. Studies conducted in Nepal [28] and Kenya [29] show higher prevalence than the present study. Our result is higher when compared with

Variable	Negative no. (%)	Positive no. (%)	Crude OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Sex						
Male	36 (37.5)	35 (53.4)	1.00		1.00	
Female	60 (62.5)	30 (46.6)	0.514 (0.271-0.975)	0.041	0.366 (0.104-1.287)	0.117
Residence						
Urban	51 (53.1)	45 (69.2)	1.00		1.00	
Rural	45 (46.9)	20 (30.8)	0.504 (0.260-0.976)	0.042	0.442 (0.137-1.425)	0.172
Educational status	5					
Illiterate	38 (39.6)	18 (27.7)	0.585 (0.296-1.154)	0.122	5.997 (0.652-55.152)	0.114
Literate	58 (60.4)	47 (72.3)	1.00		1.00	
Occupation						
Student	19 (19.8)	23 (35.3)	1.00		1.00	
Housewife	34 (35.4)	8 (12.3)	0.194 (0.073-0.518)	0.001	0.062 (0.006-0.680)	0.203
Labor	5 (5.2)	4 (6.2)	0.661 (0.155-2.813)	0.575	0.557 (0.067-4.640)	0.589
Employee	16 (16.7)	15 (23.1)	0.774 (0.305-1.963)	0.590	0.802 (0.191-3.374)	0.764
Private	14 (14.6)	7 (10.8)	0.413 (0.139-1.231)	0.112	0.118 (0.016-0.848)	0.340
Farmer	5 (5.2)	3 (4.6)	0.496 (0.105-2.347)	0.376	0.301 (0.016-5.785)	0.426
Others	3 (3.1)	5 (7.7)	1.377 (0.291-6.519)	0.687	2.728 (0.056-133.888)	0.613

TABLE 2: Multivariate analysis of MRSA and sociodemographic factors from wound infected patients attending Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

TABLE 3: Multivariate analysis of MRSA and clinical factors from wound-infected patients attending Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Variable	Negative no. (%)	Positive no. (%)	Crude OR (95% CI)	p value	Adjusted OR (95% CI)	p value
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Previous diseases						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hypertension	6 (6.3)	11 (17.0)	2.638 (0.904-7.704)	0.076	2.72 (0.482-15.363)	0.257
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Tuberculosis	5 (5.2)	3 (4.6)	0.863 (0.195-3.815)	0.846	0.000	0.998
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diabetes	10 (10.4)	10 (15.4)	1.439 (0.549-3.769)	0.459	0.686 (0.116-4.057)	0.678
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	HIV/AIDS	16 (16.7)	0	0.000	0.998	0.000	0.998
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	No chronic diseases	59 (61.4)	41 (63.1)	1.00		1.00	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Type of wound						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Trauma	7 (7.3)	10 (15.4)	2 (0.650-6.151)	0.227	1.276 (0.095-17.211)	0.854
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Burn	9 (9.4)	13 (20.0)	2.02 (0.725-5.639)	0.178	13.752 (0.104–1815.1)	0.293
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Surgical site infection	34 (35.4)	19 (29.2)	0.782 (0.351-1.746)	0.549	0.320 (0.01-10.686)	0.525
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Abrasion and skin tear	28 (29.2)	20 (30.8)	1.00		1.00	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Others	18 (18.7)	3 (4.6)	0.233 (0.060-0.900)	0.035	0.000	0.998
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Cause of wound						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Burn	10 (10.4)	14 (21.5)	2.864 (1.098-7.467)	0.031	0.226 (0.002-29.914)	0.550
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Surgery	35 (36.5)	19 (29.2)	1.110 (0.521-2.365)	0.786	0.140 (0.002-8.007)	0.341
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Gun shot	2 (2.1)	4 (6.2)	4.091 (0.095-24.07)	0.119	0.402 (0.014-15.418)	0.666
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Bite	0	3 (4.6)	0.000	0.999	0.000	0.999
Site of woundHead24 (25.0)8 (12.3)0.4 (0.139-1.147)0.0880.845 (0.137-5.205)0.856Neck5 (5.2)5 (7.7)1.2 (0.291-4.947)0.80121.405 (0.941-487.06)0.06Abdomen10 (10.4)12 (18.5)1.44 (0.487-4.255)0.50911.159 (0.733-169.916)0.083Shoulder5 (5.2)4 (6.2)0.96 (0.218-4.228)0.9571.540 (00.076-31.0620.778Buttock2 (2.1)3 (4.6)1.8 (0.265-12.228)0.54810.84 (0.436-269.42)0.146Genitalia2 (2.1)4 (6.2)2.4 (0.385-14.968)0.34975.202 (1.843-3068.17)0.202Hand18 (18.7)15 (23.1)1.001.001.00Leg28 (29.2)14 (21.5)0.6 (0.235-1.534)0.2860.441 (0.082-2.368)0.340Others2 (2.1)00.0000.9990.0000.999Hospital stay110 (15.4)0.850 (0.343-2.109)0.7260.257 (0.054-1.217)0.0872-4 day42 (43.7)19 (29.2)1.001.001.005-6 day5 (5.2)14 (21.5)6.189 (1.948-19.66)0.0025.896 (1.063-32.698)0.420> 1 week23 (24.0)22 (33.8)2.114 (0.953-4.692)0.0661.359 (0.376-4.918)0.640	Injury	45 (47.0)	22 (33.8)	1.00		1.00	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Others	4 (4.2)	3 (4.6)	1.534 (0.316-7.458)	0.596	0.000	0.998
Neck5 (5.2)5 (7.7)1.2 (0.291-4.947)0.80121.405 (0.941-487.06)0.06Abdomen10 (10.4)12 (18.5)1.44 (0.487-4.255)0.50911.159 (0.733-169.916)0.083Shoulder5 (5.2)4 (6.2)0.96 (0.218-4.228)0.9571.540 (00.076-31.0620.778Buttock2 (2.1)3 (4.6)1.8 (0.265-12.228)0.54810.84 (0.436-269.42)0.146Genitalia2 (2.1)4 (6.2)2.4 (0.385-14.968)0.34975.202 (1.843-3068.17)0.202Hand18 (18.7)15 (23.1)1.001.001.00Leg28 (29.2)14 (21.5)0.6 (0.235-1.534)0.2860.441 (0.082-2.368)0.340Others2 (2.1)00.0000.9990.0000.999Hospital stay1 day26 (27.1)10 (15.4)0.850 (0.343-2.109)0.7260.257 (0.054-1.217)0.0872-4 day42 (43.7)19 (29.2)1.001.001.005-6 day5 (5.2)14 (21.5)6.189 (1.948-19.66)0.0025.896 (1.063-32.698)0.420>1 week23 (24.0)22 (33.8)2.114 (0.953-4.692)0.0661.359 (0.376-4.918)0.640Previous wound infectionYes47 (48.9)50 (76.9)1.001.001.00	Site of wound						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Head	24 (25.0)	8 (12.3)	0.4 (0.139-1.147)	0.088	0.845 (0.137-5.205)	0.856
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Neck	5 (5.2)	5 (7.7)	1.2 (0.291-4.947)	0.801	21.405 (0.941-487.06)	0.06
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Abdomen	10 (10.4)	12 (18.5)	1.44 (0.487-4.255)	0.509	11.159 (0.733-169.916)	0.083
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Shoulder	5 (5.2)	4 (6.2)	0.96 (0.218-4.228)	0.957	1.540 (00.076-31.062	0.778
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Buttock	2 (2.1)	3 (4.6)	1.8 (0.265-12.228)	0.548	10.84 (0.436-269.42)	0.146
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Genitalia	2 (2.1)	4 (6.2)	2.4 (0.385-14.968)	0.349	75.202 (1.843-3068.17)	0.202
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hand	18 (18.7)	15 (23.1)	1.00		1.00	
Hospital stay1 day26 (27.1)10 (15.4) $0.850 (0.343-2.109)$ 0.726 $0.257 (0.054-1.217)$ 0.087 2-4 day42 (43.7)19 (29.2) 1.00 1.00 1.00 5-6 day5 (5.2)14 (21.5) $6.189 (1.948-19.66)$ 0.002 $5.896 (1.063-32.698)$ 0.420 >1 week23 (24.0)22 (33.8) $2.114 (0.953-4.692)$ 0.066 $1.359 (0.376-4.918)$ 0.640 Previous wound infectionYes47 (48.9)50 (76.9) 1.00 1.00	Leg	28 (29.2)	14 (21.5)	0.6 (0.235-1.534)	0.286	0.441 (0.082-2.368)	0.340
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Others	2 (2.1)	0	0.000	0.999	0.000	0.999
2-4 day 42 (43.7) 19 (29.2) 1.00 1.00 5-6 day 5 (5.2) 14 (21.5) 6.189 (1.948-19.66) 0.002 5.896 (1.063-32.698) 0.420 >1 week 23 (24.0) 22 (33.8) 2.114 (0.953-4.692) 0.066 1.359 (0.376-4.918) 0.640 Previous wound infection Yes 47 (48.9) 50 (76.9) 1.00 1.00	Hospital stay						
5-6 day 5 (5.2) 14 (21.5) 6.189 (1.948-19.66) 0.002 5.896 (1.063-32.698) 0.420 >1 week 23 (24.0) 22 (33.8) 2.114 (0.953-4.692) 0.066 1.359 (0.376-4.918) 0.640 Previous wound infection Yes 47 (48.9) 50 (76.9) 1.00 1.00	1 day	26 (27.1)	10 (15.4)	0.850 (0.343-2.109)	0.726	0.257 (0.054-1.217)	0.087
>1 week 23 (24.0) 22 (33.8) 2.114 (0.953-4.692) 0.066 1.359 (0.376-4.918) 0.640 Previous wound infection Yes 47 (48.9) 50 (76.9) 1.00 1.00	2–4 day	42 (43.7)	19 (29.2)	1.00		1.00	
Previous wound infection Yes 47 (48.9) 50 (76.9) 1.00 1.00	5–6 day	5 (5.2)	14 (21.5)	6.189 (1.948-19.66)	0.002	5.896 (1.063-32.698)	0.420
Yes 47 (48.9) 50 (76.9) 1.00 1.00	>1 week	23 (24.0)	22 (33.8)	2.114 (0.953-4.692)	0.066	1.359 (0.376-4.918)	0.640
	Previous wound infection						
No 49 (51.1) 15 (23.1) 3.475 (1.722–7.013) 0.001 0.605 (0.173–2.121) 0.433	Yes	47 (48.9)	50 (76.9)	1.00		1.00	
	No	49 (51.1)	15 (23.1)	3.475 (1.722-7.013)	0.001	0.605 (0.173-2.121)	0.433

Isolate					Antin	nicrobial agei	nts, n (%)			
Isolate		VA	Cd	Е	AK	TE	С	CIP	COT	GEN
MSSA $(n = 14)$	S	14 (100)	14 (100)	11 (78.6)	14/100	5 (35.7)	9 (64.3)	12 (85.7)	11 (78.6)	14 (100)
	R	0	0	3 (21.4)	0	9 (64.3)	5 (35.7)	2 (14.3)	3 (21.4)	0
MRSA $(n=65)$	S	65 (100)	63 (96.9)	46 (70.8)	65/100	18 (27.7)	47 (72.3)	59 (90.8)	37 (59.9)	61 (93.9)
	R	0	2 (3.1)	19 (29.2)	0	47 (72.3)	18 (27.7).	6 (9.2)	28 (43.1)	4 (6.1)
Total $(n = 79)$	S	79 (100)	77 (97.5)	57 (72.2)	79/100	23 (29.1)	56 (70.9)	71 (89.9)	48 (60.8)	75 (94.9)
	R	0	2 (2.5)	22 (27.8)	0	56 (70.9)	23 (29.1)	8 (10.1)	31 (39.2)	4 (5.1)

TABLE 4: Antimicrobial susceptibility pattern of MSSA and MRSA from wound-infected patients at Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

Key: VA = vancomycin, Cd = clindamycin, E = erythromycin, AK = amikacin TE = tetracycline, KF = chloramphenicol, CIP = ciprofloxacin, COT = cotrimoxazole, GEN = gentamycin.




FIGURE 1: Disk diffusion technique showing D-test inducible clindamycin resistance from wound-infected patients attending Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

TABLE 5: Susceptibility patterns of isolated *S. aureus* against erythromycin and clindamycin from wound-infected patients at Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

Phenotype	E ^s and C ^s no resistance, <i>n</i> (%)	E^{r} and C^{s} (D zone negative) MS _B , <i>n</i> (%)	E^{r} and $\mathrm{C}^{\mathrm{s}}\left(\mathrm{D}\ \mathrm{zone}\ \mathrm{positive}\right)$ iMLS _B , $n\left(\%\right)$	E^{r} and C^{r} cMLS _B , n (%)
S. $aureus (n = 79)$	57 (60.85)	1	19 (24.1)	2
MRSA $(n = 65)$	46 (70.8)	1	16 (24.6)	2
MSSA $(n = 14)$	11 (78.6)	0	3	0

Key. E^s: erythromycin sensitive, C^s: clindamycin sensitive, E^r: erythromycin resistant, C^r: clindamycin-resistant, MS: macrolide streptogramin B, iMLS_B: inducible macrolide lincosamidestreptogramin B phenotype.

researches performed in other parts of Ethiopia [24, 25] and Africa like Libya [30], Cameroon [22], and Tanzania [31]. These differences might be due to study design, period, and socioeconomic status of the population studied.

In this study, out of 79 isolated *S. aureus* isolates, 65 (82.28%) were MRSA isolates. It is comparable to studies performed in Southwest Ethiopia [32] and Nairobi, Kenya [29]. However, it is higher than the research report from Amhara, Ethiopia [24] Turkey [9], India [33–35], Nepal [28], Jordan [20], and Pakistan [36]. Furthermore, different studies in Africa too have depicted variations in the prevalence rates of MRSA in different countries [10, 22, 30, 31, 37]. This might be due to the variation in the population studied and the practice of antibiotics usage, sample size, sample type, and infection control practices.

Since the treatment of wound infection is on an empirical basis with first-line broad-spectrum antibiotics and the increase of drug resistance among pathogens causing wound infection especially *S. aureus* exists, continuously updated data on antimicrobial susceptibility patterns would be beneficial for the trend of empirical therapy. In this study, susceptibility of isolates was done on nine selected antibiotics by the disk diffusion technique which showed that MRSA tends to be resistant to a wider range of antibiotics.

In this study, MRSA isolates were showing higher resistance to tetracycline (72.3%), cotrimoxazole (43.1%), and erythromycin (29.2%). This was consistent with reports in Ethiopia [27] and elsewhere [7, 10]. The same isolate was highly sensitive to amikacin (100%), vancomycin (100%), clindamycin (96.9%), and gentamycin (94%) which is also in agreement with the research done in Tanzania [31] that reported 100% sensitivity to vancomycin and clindamycin, respectively. Remarkable susceptibility to vancomycin, amikacin, and gentamicin may be due to lesser use of these antibiotics as a result of their less availability and low cost.

In this study, vancomycin was 100% effective against both methicillin-resistant and -sensitive *S. aureus*. This was not in parallel with studies conducted in Addis Ababa,




FIGURE 2: Antibiogram of *S. aureus* and MRSA isolated from patients with wound infection attending Arba Minch Hospital, Arba Minch, South Ethiopia, April to June 2017.

Ethiopia [27], DebreMarkos, Ethiopia [24], and Kumasi, Ghana [26] which reported the variable resistance of MRSA against vancomycin.

The present study revealed that out of 79 isolated *S. aureus* tested for inducible clindamycin resistance, 19 (24.1%) were positive (D⁺- and D-test positive). This is comparable with a study conducted in Mwanza, Tanzania (28.8%) [31]. But, it is higher than that of a study conducted in Nigeria (11.2%) [10] and Bangalore, India (9.15%) [14], however lower than a study conducted in India showing the prevalence of 47.12% and 41.3%, respectively [33, 35].

The overall prevalence of inducible clindamycin resistance among MRSA isolates were 16 (24.6%), whereas among MSSA, only 3 (21.4%) isolates showed inducible clindamycin resistance. This is supported by other studies performed in Andhra, South India (23, 28.04%) [34]. On the other hand, there was a higher prevalence of 61% [31], 87.8% [33], and 54.5% [35] of MRSA exhibiting inducible clindamycin resistance in Tanzania and India, respectively.

In this study, the remaining MRSA isolates showed another phenotype like no resistance phenotype (46, 70.8%), cMLS_B (2, 3.08%), and MS (D-negative) (1, 1.54%). Constitutive phenotype prevalence was in agreement with the study conducted by Mshana et al. in Tanzania [31] and higher than that of the report by Parasa et al. [34] and Vivek et al. [33] performed in India. In general, it may be risky to use clindamycin when erythromycin testing shows resistance or intermediate even though the bacteria are sensitive to clindamycin. For this reason, routine D-testing might help clinicians to retain confidence in using clindamycin when erythromycin resistance is observed [13].

In this study, the prevalence of MDR rate of *S. aureus* isolates was 27.8%. This prevalence was slightly lower than that of the study from Ethiopia reporting 34% [38] and 32.1% in Ghana [26] and more lower than that of the report from Jimma, Ethiopia (86.3%) [32]. The possible reasons for the prevalence differences may be attributed due to type of study population and study period and MDR definition disparity may also be probable reason.

5. Conclusion

The prevalence of MRSA in Arba Minch Hospital was found to be high. It is an alarming result which needs a due attention and intervention to control the spread of drugresistant organisms. Amikacin and vancomycin were 100% effective drugs against both MRSA and MSSA isolates. However, high level of resistance was observed to tetracycline and cotrimoxazole among MRSA isolates. The incidence of inducible clindamycin resistance was also found to be too high. This may limit the therapeutic options and may lead to treatment failure. In this case, it may be very important to evaluate the susceptibility pattern of MRSA periodically.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical clearance was obtained from the ethical committee of Arba Minch University, College of Medicine and Health Sciences, and permission was obtained from Arba Minch Hospital administrators.

Consent

Informed consent was obtained from each study participants.

Disclosure

Confidentiality of the study participants was strictly maintained from sample collection up to report writing. The findings of the microbiological investigation were communicated to the respective physician for appropriate treatment of patients with effective antibiotics.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

KM, EA, and MT participated in the laboratory work, data analysis, and interpretation. AA and MM participated in the laboratory work, data analysis, and interpretation and write up of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to thank Arba Minch University for allowing us to use Medical Microbiology and Parasitology Laboratory.

References

- A. Giacometti, O. Cirioni, A. M. Schimizzi et al., "Epidemiology and microbiology of surgical wound infections," *Journal of Clinical Microbiology*, vol. 38, no. 2, pp. 918–922, 2000.
- [2] J. Posnett, F. Gottrup, H. Lundgren, and G. Saal, "The resource impact of wounds on health-care providers in Europe," *Journal of Wound Care*, vol. 18, no. 4, p. 154, 2009.
- [3] C. K. Sen, G. M. Gordillo, S. Roy et al., "Human skin wounds: a major and snowballing threat to public health and the economy," *Wound Repair and Regeneration*, vol. 17, no. 6, pp. 763–771, 2009.
- [4] K. Mwambete and D. Rugemalila, "Antibiotic resistance profiles of bacteria isolated from surgical wounds in tertiary hospitals, Tanzania," *International Journal of Current Microbiology and Applied Sciences*, vol. 4, no. 1, pp. 448–455, 2015.
- [5] G. C. M. Almeida, M. M. dos Santos, N. G. M. Lima, T. A. Cidral, M. C. N. Melo, and K. C. Lima, "Prevalence and factors associated with wound colonization by *Staphylococcus* spp. and *Staphylococcus aureus* in hospitalized patients in inland Northeastern Brazil: a cross-sectional study," *BMC Infectious Diseases*, vol. 14, no. 1, p. 328, 2014.

- [6] B. Balta and F. Derbie, "Nasal carriage of methicillin resistant Staphylococcus aureus strains among inpatients of Jimma hospital, South Western Ethiopia," *Ethiopian Journal of Health Sciences*, vol. 13, no. 2, pp. 107–116, 2003.
- [7] D. Naik and A. Teclu, "A study on antimicrobial susceptibility pattern in clinical isolates of *Staphylococcus aureus* in Eritrea," *Pan African Medical Journal*, vol. 3, no. 1, 2010.
- [8] S. Eshetie, F. Tarekegn, F. Moges, A. Amsalu, W. Birhan, and K. Huruy, "Methicillin resistant *Staphylococcus aureus* in Ethiopia: a meta-analysis," *BMC Infectious Diseases*, vol. 16, no. 1, p. 689, 2016.
- [9] N. Duran, B. Ozer, G. G. Duran, Y. Onlen, and C. Demir, "Antibiotic resistance genes & susceptibility patterns in *Staphylococci*," *Indian Journal of Medical Research*, vol. 135, no. 3, pp. 389–396, 2012.
- [10] E. G. Nwokah and S. D. Abbey, "Inducible-clindamycin resistance in *Staphylococcus aureus* isolates in Rivers State, Nigeria," *American Journal of Clinical and Experimental Medicine*, vol. 4, no. 3, pp. 50–55, 2016.
- [11] S. Uzunović, A. Ibrahimagić, F. Kamberović, M. Kunarac, M. I. Rijnders, and E. E. Stobberingh, "Inducible clindamycin resistance in methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* of inpatient, outpatient and healthy carriers in Bosnia and Herzegovina," *Medicinski Glasnik*, vol. 10, no. 2, pp. 217–224, 2013.
- [12] E. M. Zaher, "Inducible clindamycin resistance in clinical isolates of *Staphylococci*," *International Annals of Medicine*, vol. 1, no. 4, 2017.
- [13] C. D. Steward, P. M. Raney, A. K. Morrell et al., "Testing for induction of clindamycin resistance in erythromycin-resistant isolates of *Staphylococcus aureus*," *Journal of Clinical Microbiology*, vol. 43, no. 4, pp. 1716–1721, 2005.
- [14] B. Sasirekha, M. S. Usha, J. A. Amruta, S. Ankit, N. Brinda, and R. Divya, "Incidence of constitutive and inducible clindamycin resistance among hospital-associated *Staphylococcus aureus*," *3 Biotech*, vol. 4, no. 1, pp. 85–89, 2014.
- [15] C. L. Ventola, "The antibiotic resistance crisis: part 1: causes and threats," *Pharmacy and Therapeutics*, vol. 40, no. 4, pp. 277–283, 2015.
- [16] C. Lim, E. Takahashi, M. Hongsuwan et al., "Epidemiology and burden of multidrug-resistant bacterial infection in a developing country," *eLife*, vol. 5, article e18082, 2016.
- [17] S.-H. Wang, Z.-L. Sun, Y.-J. Guo et al., "Meticillin-resistant Staphylococcus aureus isolated from foot ulcers in diabetic patients in a Chinese Care Hospital: risk factors for infection and prevalence," *Journal of Medical Microbiology*, vol. 59, no. 10, pp. 1219–1224, 2010.
- [18] Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Disk Susceptibility Tests Approved the Standard: Twenty-Sixth Edition (M02-A12), Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2016.
- [19] M. McDonald, "The epidemiology of methicillin-resistant Staphylococcus aureus surgical relevance 20 years on," ANZ Journal of Surgery, vol. 67, no. 10, pp. 682–685, 1997.
- [20] M. S. Al-Zoubi, I. A. Al-Tayyar, E. Hussein, A. Al Jabali, and S. Khudairat, "Antimicrobial susceptibility pattern of *Staphylococcus aureus* isolated from clinical specimens in northern area of Jordan," *Iranian Journal of Microbiology*, vol. 7, no. 5, pp. 265–272, 2015.
- [21] L. Kitara, A. Anywar, D. Acullu, E. Odongo-Aginya, J. Aloyo, and M. Fendu, "Antibiotic susceptibility of *Staphylococcus aureus* in suppurative lesions in Lacor Hospital, Uganda," *African Health Sciences*, vol. 11, no. 3, pp. 34–39, 2011.

- [22] M. E. A. Bissong, T. Wirgham, M. A. Enekegbe, P. T. N. Niba, and F. E. T. Foka, "Prevalence and antibiotic susceptibility patterns of methicillin resistant *Staphylococcus aureus* in patients attending the Laquintinie Hospital Douala, Cameroon," *European Journal of Clinical and Biomedical Sciences*, vol. 2, no. 6, pp. 92–96, 2016.
- [23] N. Tentolouris, G. Petrikkos, N. Vallianou et al., "Prevalence of methicillin-resistant *Staphylococcus aureus* in infected and uninfected diabetic foot ulcers," *Clinical Microbiology and Infection*, vol. 12, no. 2, pp. 186–189, 2006.
- [24] A. Kahsay, A. Mihret, T. Abebe, and T. Andualem, "Isolation and antimicrobial susceptibility pattern of *Staphylococcus aureus* in patients with surgical site infection at DebreMarkos Referral Hospital, Amhara Region, Ethiopia," *Archives of Public Health*, vol. 72, no. 1, p. 16, 2014.
- [25] M. Guta, K. Aragaw, and Y. Merid, "Bacteria from infected surgical wounds and their antimicrobial resistance in Hawassa University Referral Teaching Hospital, Southern Ethiopia," *African Journal of Microbiology Research*, vol. 8, no. 11, pp. 1118–1124, 2014.
- [26] M. Saana, F. Adu, C. Agyare, S. Y. Gbedema, V. E. Boamah, and D. F. George, "Antibiotic resistance patterns of strains of *Staphylococcus aureus* isolated from patients in three hospitals in Kumasi, Ghana," *Journal of Bacteriology Research*, vol. 5, no. 3, pp. 35–40, 2013.
- [27] T. Dilnessa and A. Bitew, "Antimicrobial susceptibility pattern of *Staphylococcus aureus* with emphasize on methicilin resistance with patients postoperative and wound infections at Yekatit 12 Hospital Medical College in Ethiopia," *American Journal of Clinical and Experimental Medicine*, vol. 4, no. 1, pp. 7–12, 2016.
- [28] A. Kshetry, B. Lekhaka, and B. Raghubanshib, "Antibiogram of bacteria isolated from wound exudates," *International Journal of Biological and Medical Research*, vol. 6, no. 2, pp. 4997–5002, 2015.
- [29] E. K. Maina, C. Kiiyukia, C. N. Wamae, P. G. Waiyaki, and S. Kariuki, "Characterization of methicillin-resistant *Staphylococcus aureus* from skin and soft tissue infections in patients in Nairobi, Kenya," *International Journal of Infectious Diseases*, vol. 17, no. 2, pp. e115–e119, 2013.
- [30] A. A. Zorgani, O. Elahmer, A. Abaid et al., "Vancomycin susceptibility trends of methicillin-resistant *Staphylococcus aureus* isolated from burn wounds: a time for action," *Journal* of *Infection in Developing Countries*, vol. 9, no. 11, pp. 1284–1288, 2015.
- [31] S. Mshana, E. Kamugisha, M. Miramb et al., "Prevalence of clindamycin inducible resistance among methicillin-resistant *Staphylococcus aureus* at Bugando Medical Centre, Mwanza, Tanzania," *Tanzania Journal of Health Research*, vol. 11, no. 2, 2009.
- [32] G. Godebo, G. Kibru, and H. Tassew, "Multidrug-resistant bacterial isolates in infected wounds at Jimma University Specialized Hospital, Ethiopia," *Annals of Clinical Microbiology and Antimicrobials*, vol. 12, no. 1, p. 17, 2013.
- [33] J. S. Vivek, S. Mukesh, K. Manpreet et al., "Prevalence of inducible clindamycin resistance among community-and hospital-associated *Staphylococcus aureus* isolates in a tertiary care hospital in India," *Biomedical Research*, vol. 22, no. 4, pp. 465–469, 2011.
- [34] L. S. Parasa, S. R. Tumati, S. P. Chigurupati et al., "Prevalence of induced clindamycin resistance in methicillin resistant *Staphylococcus aureus* from hospital population of coastal Andhara Pradesh, South India," *Archives of Clinical Microbiology*, vol. 2, no. 1, 2011.

- [35] S. Ghosh and M. Banerjee, "Methicillin resistance & inducible clindamycin resistance in *Staphylococcus aureus*," *Indian Journal of Medical Research*, vol. 143, no. 3, p. 362, 2016.
- [36] M. Saaiq, S. Ahmad, and M. S. Zaib, "Burn wound infections and antibiotic susceptibility patterns at Pakistan Institute of Medical Sciences, Islamabad, Pakistan," *World Journal of Plastic Surgery*, vol. 4, no. 1, pp. 9–15, 2015.
- [37] E. Maingi, M. Mutugi, Z. Osiemo-Langat, and S. Muya, "Antibiotic sensitivity of *Staphylococcus aureus* isolated from patients attending Ruiru District Hospital, Kenya August to November 2012," *International Journal of Tropical Disease & Health*, vol. 8, no. 4, pp. 134–143, 2015.
- [38] M. Mama, A. Abdissa, and T. Sewunet, "Antimicrobial susceptibility pattern of bacterial isolates from wound infection and their sensitivity to alternative topical agents at Jimma University Specialized Hospital, South-West Ethiopia," *Annals of Clinical Microbiology and Antimicrobials*, vol. 13, no. 1, p. 14, 2014.